Aptevo Therapeutics (APVO) Gains from Investment Securities (2016 - 2023)
Historic Gains from Investment Securities for Aptevo Therapeutics (APVO) over the last 9 years, with Q1 2023 value amounting to $467586.0.
- Aptevo Therapeutics' Gains from Investment Securities rose 136184.58% to $467586.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $467586.0, marking a year-over-year increase of 136184.58%. This contributed to the annual value of $364266.0 for FY2022, which is 892.73% up from last year.
- According to the latest figures from Q1 2023, Aptevo Therapeutics' Gains from Investment Securities is $467586.0, which was up 136184.58% from $400000.0 recorded in Q3 2022.
- Aptevo Therapeutics' 5-year Gains from Investment Securities high stood at $467586.0 for Q1 2023, and its period low was $292.0 during Q1 2021.
- Moreover, its 5-year median value for Gains from Investment Securities was $334938.0 (2019), whereas its average is $283220.3.
- In the last 5 years, Aptevo Therapeutics' Gains from Investment Securities plummeted by 9992.49% in 2021 and then surged by 1085410.96% in 2022.
- Quarter analysis of 5 years shows Aptevo Therapeutics' Gains from Investment Securities stood at $334938.0 in 2019, then fell by 2.7% to $325904.0 in 2020, then rose by 2.61% to $334412.0 in 2021, then grew by 19.61% to $400000.0 in 2022, then rose by 16.9% to $467586.0 in 2023.
- Its last three reported values are $467586.0 in Q1 2023, $400000.0 for Q3 2022, and $400000.0 during Q2 2022.